Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.

ABSTRACT:

Importance

Infection with the respiratory syncytial virus (RSV) is the leading cause of hospitalizations in children, accounting for more than 90,000 hospitalizations every year in the United States. For children who are at risk for severe RSV infections, the American Academy of Pediatrics recommends immunoprophylaxis with a series of up to 5 injections of the antibody palivizumab administered monthly, beginning on November 1 of each year. However, many practitioners initiate injections at the onset of RSV season as indicated by local surveillance.

Objectives

To evaluate the effectiveness of current regimens for palivizumab injections across different cities and to design an optimized regimen.

Design, setting, and participants

We performed a mathematical modeling stud

SUBMITTER: Gutfraind A 

PROVIDER: S-EPMC4391881 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature